Because GnRH-II antagonists appear to be suitable drugs for efficacious and less-toxic endocrine therapy for endometrial and ovarian cancers, the question arises whether GnRH-II antagonist treatment could also be a new therapeutic option for breast cancers. Here, GNRH2 is linked to breast carcinoma.